lobbying_activities: 3006718

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3006718	eee336a5-93ac-42fd-b7b1-0abf496e2f3d	Q2	EMERGENT BIOSOLUTIONS INC.	304931	EMERGENT BIOSOLUTIONS INC	2023	second_quarter	DIS	Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding for FY24. Substance Abuse and Mental Health Block Grant (SABG) funding for FY24. NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone. FAA reauthorization - increasing access to naloxone.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		720000	0	0	2023-07-17T11:34:34-04:00